Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18331786 | 1.00 | HPGD (0.58) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL17928596 | 1.00 | HPGD (0.58) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL25366205 | 1.00 | HPGD (0.58) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL25366713 | 0.95 | HPGD (0.54) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL23997789 | 0.89 | ALDH1A1 (0.47) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL25365817 | 0.86 | HPGD (0.46) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL1687921 | 0.80 | ALDH1A1 (0.54) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL3487800 | 0.80 | ALDH1A1 (0.54) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL13498450 | 0.80 | ALDH1A1 (0.54) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL8271067 | 0.79 | ALDH1A1 (0.44) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363126-A1 | PROCESS FOR THE PREPARATION OF PIPERINE | CIPLA LIMITED (IN) | 2021-11-25 | — | — | US | disclosed |
| EP-2529622-B1 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170007611-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20160361315-A1 | IBRUTINIB PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-12-15 | — | — | US | disclosed |
| US-9409911-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-9394312-B1 | Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2016-07-19 | — | — | US | disclosed |
| US-9266893-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-02-23 | — | — | US | disclosed |
| US-9212185-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-9206189-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9193735-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-11-24 | — | — | US | disclosed |
| US-20120122894-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120108612-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120088912-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20110184001-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-7960396-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | HPGD 2986/4885SMN1; SMN2 4262/4885ALDH1A1 4459/4885 |
| US-20170007611-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | HPGD 2986/4885SMN1; SMN2 4262/4885ALDH1A1 4459/4885 |
| US-20120088912-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | HPGD 2986/4885SMN1; SMN2 4262/4885ALDH1A1 4459/4885 |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | HPGD 2986/4885SMN1; SMN2 4262/4885ALDH1A1 4459/4885 |
| US-20120122894-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | HPGD 2986/4885SMN1; SMN2 4262/4885ALDH1A1 4459/4885 |
| US-20210363126-A1 | PROCESS FOR THE PREPARATION OF PIPERINE | PTMA, ITPA, PRPH | HPGD 1264/4885SMN1; SMN2 648/4885ALDH1A1 407/4885 |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | HPGD 2986/4885SMN1; SMN2 4262/4885ALDH1A1 4459/4885 |
| US-20110184001-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | HPGD 2986/4885SMN1; SMN2 4262/4885ALDH1A1 4459/4885 |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | BTK, LCK, LYN | HPGD 2586/4885SMN1; SMN2 4293/4885ALDH1A1 3930/4885 |
| US-20120108612-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | HPGD 2986/4885SMN1; SMN2 4262/4885ALDH1A1 4459/4885 |
| US-20160361315-A1 | IBRUTINIB PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | BTK, SYK, BCL9 | HPGD 1921/4885SMN1; SMN2 4276/4885ALDH1A1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.